Diabetes medication associated with slower progression of retina disease

Patients with diabetes who take the medication rosiglitazone may be less likely to develop the eye disease proliferative diabetic retinopathy or to experience reductions in visual acuity (sharpness), according to a report in the June issue of Archives of Ophthalmology.

Proliferative diabetic retinopathy occurs when existing blood vessels in the retina are blocked or damaged and new, tiny blood vessels form, according to background information in the article. It one of is the most common causes of severe vision loss among working-age Americans, and few effective therapies exist to delay its progression.

Lucy Q. Shen, M.D., of the Jules Stein Eye Institute, University of California–Los Angeles, and colleagues reviewed the medical records of 124 patients who were treated with rosiglitazone and who were receiving medical and ophthalmic care at the Joslin Diabetes Center in Boston between May 2002 and May 2003. They compared these patients to 158 patients who also had diabetes but were not taking rosiglitazone or a similar medication.

At the beginning of the study, 14 eyes of those in the rosiglitazone group (6.4 percent) and 24 eyes of those in the control group (9.3 percent) had severe non-proliferative diabetic retinopathy, an earlier stage of the disease in which new blood vessels have not yet developed. Among those, 7.7 percent of those in the rosiglitazone group and 29.2 percent of those in the control group progressed to proliferative diabetic retinopathy after one year. After three years, 19.2 percent in the rosiglitazone group and 47.4 percent in the control group had progressed from non-proliferative to proliferative diabetic retinopathy—a 59.5 percent relative risk reduction in the rosiglitazone group.

In addition, fewer eyes in the rosiglitazone group than in the control group experienced a loss in visual acuity of three or more lines on the vision chart (.5 percent vs. 14.5 percent) during an average of 2.8 years of follow-up.

Rosiglitazone may delay the progression of retinopathy and preserve vision by reducing the formation of new blood vessels, a process known as angiogenesis, the authors note. "However, because this study does not rigorously prove that rosiglitazone either reduces the incidence of proliferative diabetic retinopathy or prevents loss of visual acuity, and because there may be adverse effects from therapy, rosiglitazone treatment of patients with diabetes specifically to reduce these ophthalmic complications is not advocated at this time," they write. Known adverse effects include fluid build-up, abnormal liver function test and the worsening of congestive heart failure.

Source: JAMA and Archives Journals

Related stories:

Intensive blood sugar treatment in trial of diabetes and cardiovascular disease changed
The National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health has stopped one treatment within a large, ongoing North American clinical trial of diabetes and cardiovascular disease 18 months early due to safety concerns after review of available data, although the study will continue.
Long-term use of diabetes drug increases heart attack risk by more than 40 percent
An analysis of four studies involving more than 14,000 patients found that long-term use of the diabetes drug rosiglitazone (Avandia®) increased the risk of heart attack by 42 percent and doubled the risk of heart failure, according to a new report from researchers at Wake Forest University School of Medicine and colleagues. There was no effect on death from cardiovascular causes.
Weight-Loss Supplement Shows Good And Bad Traits
A supplement some people turn to in hopes of losing a few pounds may have some previously unknown, unsavory side effects, suggest two new studies.
Class of diabetes drugs carries significant cardiovascular risks
A class of oral drugs used to treat type 2 diabetes may make heart failure worse, according to an editorial published online in Heart Wednesday by two Wake Forest University School of Medicine faculty members.
No 'convincing evidence' that glitazones work better than older diabetes drugs
There is no convincing evidence that the newer class of diabetes drugs, known as glitazones, offer real advantages over other diabetes drugs, when used on their own, concludes the Drug and Therapeutics Bulletin (DTB).
Protein target for diabetes drug regulates blood pressure
University of Iowa researchers have identified a molecular pathway in blood vessels that controls blood pressure and vascular function and may help explain why certain drugs for type II diabetes also appear to lower patients' blood pressure. The study is published in the March 5 issue of Cell Metabolism.
'Micro' livers could aid drug screening
MIT researchers have devised a novel way to create tiny colonies of living human liver cells that model the full-sized organ. The work could allow better screening of new drugs that are potentially harmful to the liver and reduce the costs associated with their development.
Reanalysis of controversial meta-analysis says writing off rosiglitazone may be premature
Rosiglitazone, a drug marketed by GlaxoSmithKline as Avandia® for the treatment of type 2 diabetes, came under fire after an article published online May 21 by the New England Journal of Medicine linked it to significantly increased risk of heart attack and cardiovascular death.

News discussion:

Medicine & Health news